DiaMonTech GmbH published remarkable results of a clinical study, confirming the accuracy of its non-invasive blood glucose-monitoring technology. In the clinical study, the blood glucose of 100 volunteers was measured using DiaMonTech's laser-based, non-invasive technology and compared to a clinically established invasive reference measurement method. The non-invasive method achieved measurement results with a mean error of only 11%, which is otherwise only achieved with (minimally-) invasive devices. The convincing results confirm DiaMonTech's plans to launch a product for diabetics for the non-invasive measurement of blood glucose on the market as early as next year. A total of 59 healthy persons and 41 diabetics between the age of 18 to over 70 years participated in the study. The participants were asked to attend the measurement fasting, with a low blood glucose level. During the test period, blood glucose was increased with a glucose-containing drink for healthy volunteers. For diabetes patients, the usual increase in blood glucose after a meal was used. This ensured that measurement results were available for both, low and high blood glucose levels. DiaMonTech's non-invasive measurement delivered accurate measurements over the entire measuring range from about 50 mg/dL to over 350 mg/dL. In the study, DiaMonTech's non-invasive glucose measurement yielded 99.1% precise measurement results, demonstrating accuracy for men and women - both, healthy and diabetic - between 18 and over 70 years of age. The values result from a so-called Consensus Error Grid Analysis, in which the measurement results of the DiaMonTech technology are compared with those of the simultaneously performed invasive measurement and divided into different zones (A-E). All measurement results in zones A and B meet the high accuracy requirements.